Immatics (IMTX) Competitors $7.12 +0.27 (+3.94%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$7.02 -0.09 (-1.33%) As of 09/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMTX vs. IMVT, XENE, VKTX, OGN, KNSA, NAMS, BHC, GMTX, CGON, and MLYSShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Immunovant (IMVT), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), CG Oncology (CGON), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Immatics vs. Its Competitors Immunovant Xenon Pharmaceuticals Viking Therapeutics Organon & Co. Kiniksa Pharmaceuticals International NewAmsterdam Pharma Bausch Health Cos Gemini Therapeutics CG Oncology Mineralys Therapeutics Immunovant (NASDAQ:IMVT) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends. Do insiders & institutionals believe in IMVT or IMTX? 47.1% of Immunovant shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor IMVT or IMTX? In the previous week, Immatics had 3 more articles in the media than Immunovant. MarketBeat recorded 6 mentions for Immatics and 3 mentions for Immunovant. Immunovant's average media sentiment score of 0.58 beat Immatics' score of 0.29 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, IMVT or IMTX? Immatics has higher revenue and earnings than Immunovant. Immatics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$413.84M-$2.85-5.23Immatics$168.65M5.13$16.47M-$0.65-10.95 Do analysts recommend IMVT or IMTX? Immunovant presently has a consensus target price of $33.60, indicating a potential upside of 125.50%. Immatics has a consensus target price of $15.00, indicating a potential upside of 110.67%. Given Immunovant's higher possible upside, equities analysts clearly believe Immunovant is more favorable than Immatics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83Immatics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has more volatility & risk, IMVT or IMTX? Immunovant has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Immatics has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Is IMVT or IMTX more profitable? Immunovant has a net margin of 0.00% compared to Immatics' net margin of -59.29%. Immatics' return on equity of -15.60% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -80.99% -72.23% Immatics -59.29%-15.60%-12.31% SummaryImmatics beats Immunovant on 9 of the 15 factors compared between the two stocks. Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$832.62M$3.16B$5.76B$10.51BDividend YieldN/A2.36%5.53%4.57%P/E Ratio-10.9521.0476.0626.61Price / Sales5.13252.06472.8291.51Price / Cash28.0446.3537.4661.85Price / Book1.399.7813.586.45Net Income$16.47M-$52.73M$3.29B$271.57M7 Day Performance18.08%3.16%1.83%2.61%1 Month Performance25.13%4.69%4.02%7.28%1 Year Performance-39.04%16.37%77.05%29.60% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics2.8193 of 5 stars$7.12+3.9%$15.00+110.7%-39.5%$832.62M$168.65M-10.95260IMVTImmunovant2.0142 of 5 stars$15.53-3.9%$33.60+116.4%-47.4%$2.82BN/A-5.45120Positive NewsXENEXenon Pharmaceuticals2.5363 of 5 stars$35.99-0.6%$53.30+48.1%-5.9%$2.79B$7.50M-10.14210Positive NewsVKTXViking Therapeutics4.4153 of 5 stars$24.08-2.9%$87.50+263.4%-61.6%$2.79BN/A-15.7420Analyst ForecastOGNOrganon & Co.4.5663 of 5 stars$10.39-2.5%$17.33+66.9%-46.4%$2.77B$6.40B3.864,000Positive NewsKNSAKiniksa Pharmaceuticals International2.6524 of 5 stars$36.56-1.5%$41.17+12.6%+47.6%$2.75B$423.24M914.23220Positive NewsNAMSNewAmsterdam Pharma3.1389 of 5 stars$24.12-0.3%$41.55+72.2%+72.4%$2.72B$45.56M-14.894Positive NewsBHCBausch Health Cos4.612 of 5 stars$7.17-1.2%$9.00+25.5%-16.0%$2.69B$9.86B27.5820,700GMTXGemini TherapeuticsN/A$59.82-0.8%N/A+27.8%$2.59BN/A-59.8230CGONCG Oncology2.5467 of 5 stars$34.60+3.8%$53.91+55.8%-4.3%$2.54B$1.14M-19.5561Insider TradeMLYSMineralys Therapeutics2.8337 of 5 stars$36.21-2.4%$43.50+20.1%+228.8%$2.46BN/A-10.1728 Related Companies and Tools Related Companies Immunovant Competitors Xenon Pharmaceuticals Competitors Viking Therapeutics Competitors Organon & Co. Competitors Kiniksa Pharmaceuticals International Competitors NewAmsterdam Pharma Competitors Bausch Health Cos Competitors Gemini Therapeutics Competitors CG Oncology Competitors Mineralys Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMTX) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMTX Stock Alerts